Back to companies

Turning Point Therapeutics Inc: Overview

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Turning Point Therapeutics Inc (TP therapeutics), a subsidiary of Bristol-Myers Squibb Co, is a biopharmaceutical company. It designs and develops clinical stage small molecule, targeted oncology therapies to address key limitations of existing lung cancer therapies. The company's pipeline products include Repotrectinib, macrocyclic tyrosine kinase inhibitor, TPX-0022, multi-targeted kinase inhibitor, TPX-0046, a multi-targeted orally bioavailable TKI, TPX - 013 and ALK inhibitor. TP therapeutics provides clinical trial activities such as TRIDENT-1 and compassionate use programs. The company’s macrocyclic platform addresses the issues of emerging treatment resistance and toxicities that limit duration of treatment. It operates in the US and Switzerland. TP Therapeutics is headquartered in San Diego, California, the US.

Gain a 360-degree view of Turning Point Therapeutics Inc and make more informed decisions for your business Gain a 360-degree view of Turning Point Therapeutics Inc and make more informed decisions for your business Register your interest
Headquarters United States of America

Address Suite 200, 10628 Science Center Drive, San Diego, California, 92121


Telephone 1 858 9265251

No of Employees 267

Industry Pharmaceuticals and Healthcare

Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Register your interest

Turning Point Therapeutics Inc premium industry data and analytics

60+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Turning Point Therapeutics Inc’s relevant decision makers and contact details.

20+

Catalyst Calendar

Proactively evaluate Turning Point Therapeutics Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

14+

Pipeline Drugs

Identify which of Turning Point Therapeutics Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

11+

Clinical Trials

Determine Turning Point Therapeutics Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

5

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

4

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

Products and Services

Products Services
Elzovantinib Clinical Trials
Repotrectinib Investigator Sponsored Research
TPX-0022
XYZ
XYZ
XYZ
Understand Turning Point Therapeutics Inc portfolio and identify potential areas for collaboration Understand Turning Point Therapeutics Inc portfolio and identify potential areas for collaboration Register your interest
Image for loader

Competitor Comparison

Key Parameters Turning Point Therapeutics Inc Protagonist Therapeutics Inc Y-mAbs Therapeutics Inc BioAtla Inc Biopact Cellular Transport Inc
Headquarters United States of America United States of America United States of America United States of America United States of America
City San Diego Newark Princeton San Diego Austin
State/Province California California New Jersey California Texas
No. of Employees 267 128 107 61 -
Entity Type Private Public Private Public Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Register your interest
Executives
Name Position Board Since Age
Athena Countouriotis Chief Executive Officer; President Senior Management - -
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Gain insight into Turning Point Therapeutics Inc key executives to enhance your sales strategy Gain insight into Turning Point Therapeutics Inc key executives to enhance your sales strategy Register your interest
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Why are you leaving?